Published Year: 2021
Carrier Screening Market - A Global and Regional Analysis: Focus on Type, Product, Carrier Screening
The global carrier screening market is projected to reach $4,479.0 million by 2031, growing...
Market Research Report
A quick peek into the report
Table of Contents
1.1 Inclusion and Exclusion
2.1 Overview: Report Scope
2.2 Segmentation of the Global NIPT Market
2.3 Assumptions and Limitations
2.4 Key Questions Answered in the Report
2.5 Base Year and Forecast Period
3.1 Overview: Report Methodology
3.2 Primary Data Sources
3.3 Secondary Data Sources
3.4 Market Estimation Model
3.5 Criteria for Company Profiling
4.1 Introduction
4.2 Factors Influencing the Adoption of NIPT
4.3 NIPT Approach
4.4 Different Methods of NIPT
4.5 Benefits and Risks Associated with NIPT
4.6 Chromosomal Aneuploidy
4.7 Features and Incidence Rate of Major Chromosomal Aneuploidies
4.8 Technological Advancements
4.9 World Economic Outlook of Non-Invasive Prenatal Testing Market, 2019
4.10 Global Footprint
5.1 Overview
5.2 Impact Analysis
5.3 Market Drivers
5.3.1 Increased Emphasis on Early Detection and Prevention
5.3.2 Availability of Advanced Screening Technologies
5.3.3 Increasing Consumer Demand
5.3.4 Shifting of Reimbursement Policies Toward More Genetics Coverage
5.3.5 High Incidence Rate of Down’s Syndrome
5.3.6 Rising Average Maternal Age
5.3.7 Increasing Prevalence of Genetic and Congenital Disorders
5.4 Market Restraints
5.4.1 Stringent Regulatory Guidelines and Ethical Hurdles
5.4.2 Limitations of NIPT
5.4.3 Lack of Awareness Among Consumers
5.4.4 Alternative Screening and Testing Methods
5.5 Market Opportunities
5.5.1 Capitalizing on the Potential Presented by the Emerging Markets in Asia
5.5.2 Availability of Direct-to-Consumer Tests
5.5.3 Focus on Pre-Implantation Genetic Diagnosis
6.1 Regulatory Framework
6.1.1 Regulatory Scenario in the U.S.
6.1.2 Regulatory Scenario in Canada
6.1.3 Regulatory Scenario in the U.K.
6.1.4 Regulatory Scenario in Germany
6.1.5 Regulatory Scenario in France
6.1.6 Regulatory Scenario in Spain
6.1.7 Regulatory Scenario in Italy
6.1.8 Regulatory Scenario in the Netherlands
6.1.9 Regulatory Scenario in China
6.1.10 Regulatory Scenario in India
6.1.11 Regulatory Scenario in Australia
6.1.12 Regulatory Scenario in Japan
6.2 Clinical Laboratory Improvement Amendments (CLIA) Program
6.2.1 Regulatory Authorities Involved in CLIA Program
6.3 Cost and Access
6.4 Reimbursement Scenario
6.5 Funding Scenario
6.6 Supply Chain
6.7 Impact of COVID-19 Outbreak on the Global NIPT Market
7.1 Overview
7.2 Key Developments and Strategies
7.2.1 New Offerings
7.2.2 Partnerships and Alliances
7.2.3 Product Approvals
7.2.4 Business Expansions
7.2.5 Merger and Acquisition Activities
7.2.6 Others
7.3 Market Share Analysis, by Company
7.4 Growth Share Analysis (Opportunity Mapping)
7.4.1 by Platform
8.1 Overview
8.2 Panorama and Vistara
8.3 MaterniT GENOME, MaterniT 21 PLUS, and informaSeq
8.4 Verifi and Verifi Plus Prenatal Tests
8.5 Harmony Test
8.6 NIFTY Test and NIFTY-Test Pro
8.7 QNatal Advanced
8.8 PrenaTest, GeneSafe, and PrenatalSAFE
8.9 Bambni Test
8.10 IONA and Sage
8.11 Others
9.1 Overview
9.2 cfDNA
9.3 FCMB
10.1 Overview
10.2 Next-Generation Sequencing
10.3 PCR
10.4 Others
11.1 Overview
11.2 Trisomy Detection
11.3 Microdeletion Detection
11.4 Sex Chromosome Aneuploidy Detection
11.5 Others
12.1 Overview
12.2 Hospital
12.3 Clinics
12.4 Diagnostic Labs
12.5 Others
13.1 Overview
13.2 North America
13.2.1 Overview
13.2.1.1 By Value and Volume
13.2.1.2 By Value and Volume (by Country)
13.2.1.3 Pricing Analysis by Leading NIPT Test
13.2.2 U.S.
13.2.2.1 By Value
13.2.2.2 By Volume
13.2.2.3 Organizations Offering NIPT Test
13.2.2.4 Market Share Analysis
13.2.2.5 Pricing Analysis by Leading NIPT Test
13.2.3 Canada
13.2.3.1 By Value
13.2.3.2 By Volume
13.2.3.3 Organizations Offering NIPT Test
13.2.3.4 Market Share Analysis
13.2.3.5 Pricing Analysis by Leading NIPT Test
13.3 Europe
13.3.1 Overview
13.3.1.1 By Value and Volume
13.3.1.2 By Value and Volume (by Country)
13.3.1.3 Pricing Analysis by Leading NIPT Test
13.3.2 Germany
13.3.2.1 By Value
13.3.2.2 By Volume
13.3.2.3 Organizations Offering NIPT Test
13.3.2.4 Market Share Analysis
13.3.3 France
13.3.3.1 By Value
13.3.3.2 By Volume
13.3.3.3 Organizations Offering NIPT Test
13.3.3.4 Market Share Analysis
13.3.4 Italy
13.3.4.1 By Value
13.3.4.2 By Volume
13.3.4.3 Organizations Offering NIPT Test
13.3.4.4 Market Share Analysis
13.3.5 U.K.
13.3.5.1 By Value
13.3.5.2 By Volume
13.3.5.3 Organizations Offering NIPT Test
13.3.5.4 Market Share Analysis
13.3.6 Spain
13.3.6.1 By Value
13.3.6.2 By Volume
13.3.6.3 Organizations Offering NIPT Test
13.3.6.4 Market Share Analysis
13.3.7 Russia
13.3.7.1 By Value
13.3.7.2 By Volume
13.3.7.3 Organizations Offering NIPT Test
13.3.7.4 Market Share Analysis
13.3.8 Poland
13.3.8.1 By Value
13.3.8.2 By Volume
13.3.8.3 Organizations Offering NIPT Test
13.3.8.4 Market Share Analysis
13.3.9 Netherlands
13.3.9.1 By Value
13.3.9.2 By Volume
13.3.9.3 Organizations Offering NIPT Test
13.3.9.4 Market Share Analysis
13.3.10 Belgium
13.3.10.1 By Value
13.3.10.2 By Volume
13.3.10.3 Organizations Offering NIPT Test
13.3.10.4 Market Share Analysis
13.3.11 Switzerland
13.3.11.1 By Value
13.3.11.2 By Volume
13.3.11.3 Organizations Offering NIPT Test
13.3.11.4 Market Share Analysis
13.3.12 Denmark
13.3.12.1 By Value
13.3.12.2 By Volume
13.3.12.3 Organizations Offering NIPT Test
13.3.12.4 Market Share Analysis
13.3.13 Sweden
13.3.13.1 By Value
13.3.13.2 By Volume
13.3.13.3 Organizations Offering NIPT Test
13.3.13.4 Market Share Analysis
13.3.14 Rest-of-Europe
13.3.14.1 By Value
13.3.14.2 By Volume
13.4 Asia-Pacific
13.4.1 Overview
13.4.1 China
13.4.1.1 By Value
13.4.1.2 By Volume
13.4.2 Japan
13.4.2.1 By Value
13.4.2.2 By Volume
13.4.3 India
13.4.3.1 By Value
13.4.3.2 By Volume
13.4.4 Australia
13.4.4.1 By Value
13.4.4.2 By Volume
13.4.5 South Korea
13.4.5.1 By Value
13.4.5.2 By Volume
13.4.6 Hong Kong
13.4.6.1 By Value
13.4.6.2 By Volume
13.4.7 Malaysia
13.4.7.1 By Value
13.4.7.2 By Volume
13.4.8 Indonesia
13.4.8.1 By Value
13.4.8.2 By volume
13.4.9 Vietnam
13.4.9.1 By Value
13.4.9.2 By Volume
13.4.10 Thailand
13.4.10.1 By Value
13.4.10.2 By Volume
13.4.11 Philippines
13.4.11.1 By Value
13.4.11.2 By Volume
13.4.12 Rest-of-APAC
13.4.12.1 By Value
13.4.12.2 By Volume
13.5 Latin America
13.5.1 By Value
13.5.2 By Volume
13.6 Rest-of-the-World
13.6.1 By Value
13.6.2 By Volume
14.1 Overview
14.2 Agilent Technologies, Inc.
14.2.1 Company Overview
14.2.2 Role of Agilent Technologies, Inc. in the Global NIPT Market
14.2.3 Financials
14.2.4 Key Insights About Financial Health of the Company
14.2.5 SWOT Analysis
14.3 F. Hoffmann-La Roche Ltd
14.3.1 Company Overview
14.3.2 Role of F. Hoffmann-La Roche Ltd in the Global NIPT Market
14.3.3 Financials
14.3.4 Key Insights About Financial Health of the Company
14.3.5 SWOT Analysis
14.4 PerkinElmer, Inc.
14.4.1 Company Overview
14.4.2 Role of PerkinElmer, Inc. in the Global NIPT Market
14.4.3 Financials
14.4.4 Key Insights About Financial Health of the Company
14.4.5 SWOT Analysis
14.5 Quest Diagnostics Incorporated
14.5.1 Company Overview
14.5.2 Role of Quest Diagnostics Incorporated in the Global NIPT Market
14.5.3 Financials
14.5.4 SWOT Analysis
14.6 Illumina, Inc.
14.6.1 Company Overview
14.6.2 Role of Illumina, Inc. in the Global NIPT Market
14.6.3 Financials
14.6.4 Key Insights About Financial Health of the Company
14.6.5 SWOT Analysis
14.7 Myriad Genetics, Inc.
14.7.1 Company Overview
14.7.2 Role of Myriad Genetics, Inc. in the NIPT Market
14.7.3 Financials
14.7.4 Key Insights About Financial Health of the Company
14.7.5 SWOT Analysis
14.8 BGI
14.8.1 Company Overview
14.8.2 Role of BGI in the NIPT Market
14.8.3 SWOT Analysis
14.9 CENTOGENE N.V.
14.9.1 Company Overview
14.9.2 Role of CENTOGENE N.V. in the NIPT Market
14.9.3 Financials
14.9.4 Key Insights About Financial Health of the Company
14.9.5 SWOT Analysis
14.10 Laboratory Corporation of America Holdings
14.10.1 Company Overview
14.10.2 Role of Laboratory Corporation of America Holdings in the NIPT Market
14.10.3 Financials
14.10.4 SWOT Analysis
14.11 MedGenome Inc.
14.11.1 Company Overview
14.11.2 Role of MedGenome Inc. in the Global NIPT Market
14.11.3 SWOT Analysis
14.12 Annoroad Gene Technology
14.12.1 Company Overview
14.12.2 Role of Annoroad Gene Technology in the NIPT Market
14.12.3 SWOT Analysis
14.13 Natera, Inc.
14.13.1 Company Overview
14.13.2 Role of Natera, Inc. in the Global NIPT Market
14.13.3 Financials
14.13.4 Key Insights About Financial Health of the Company
14.13.5 SWOT Analysis
14.14 Yourgene Health PLC
14.14.1 Company Overview
14.14.2 Role of Yourgene Health PLC in the NIPT Market
14.14.3 Financials
14.14.4 SWOT Analysis
14.15 Next Biosciences
14.15.1 Company Overview
14.15.2 Role of Next Biosciences in the NIPT Market
14.15.3 SWOT Analysis
14.16 Eurofins Scientific
14.16.1 Company Overview
14.16.2 Role of Eurofins Scientific in the NIPT Market
14.16.3 Financials
14.16.4 SWOT Analysis
Table 1: Major Chromosomal Aneuploidies
Table 2: Technological Approach for NIPT
Table 3: Impact Analysis of Market Drivers
Table 4: Impact Analysis of Market Restraints
Table 5: Risk of Chromosomal Abnormality w.r.t Maternal Age
Table 6: Chromosome (Gene) Defects Prevalence Per Year in the U.S.
Table 7: List of Regulatory Authorities Involved in CLIA Program
Table 8: Major Funding Activities (January 2017-June 2020)
Table 9: Key Companies Offering cfDNA-Based NIPT Solution
Table 10: Key Companies Offering FCMB-Based NIPT Solution
Table 11: Key Companies Offering NGS-Based NIPT Solution
Table 12: Key Companies Offering PCR-Based NIPT Solution
Table 13: Key Companies Offering Other Platform-Based NIPT Solution
Table 14: Key Companies Offering NIPT Solution for Trisomy Detection
Table 15: Key Companies Offering NIPT Solution for Microdeletion Detection
Table 16: Key Companies Offering NIPT Solution for SCA Detection
Figure 1: Global NIPT Market (by Region), by Revenue, $Million, 2020-2031
Figure 2: Global NIPT Market (by Region), by Volume, Thousand Units, 2020 and 2031
Figure 3: Impact of Market Drivers and Market Restraints
Figure 4: Share of Key Developments and Strategies, January 2017-October 2021
Figure 5: Market Statistics
Figure 6: Global NIPT Market Share (by Test), 2020-2031
Figure 7: Global NIPT Market Share (by Method), 2020-2031
Figure 8: Global NIPT Market Share (by Platform), 2020-2031
Figure 9: Global NIPT Market Share (by Application), 2020-2031
Figure 10: Global NIPT Market Share (by End User), 2020-2031
Figure 11: Global NIPT Market Segmentation
Figure 12: Global NIPT Market Methodology
Figure 13: Primary Research Methodology
Figure 14: Bottom-Up Approach (Segment-Wise Analysis)
Figure 15: Top-Down Approach (Segment-Wise Analysis)
Figure 16: Prenatal Testing Timeline During Pregnancy
Figure 17: Different Indications for NIPT
Figure 18: NIPT Approach
Figure 19: Benefits and Risks of NIPT
Figure 20: Features of the Major Chromosome Aneuploidies
Figure 21: Incidence Rate of Major Chromosome Aneuploidies
Figure 22: Ecosystem Players of Global Non-Invasive Prenatal Testing Market
Figure 23: Global NIPT Market, by Revenue, $Million, 2020-2031
Figure 24: Global NIPT Market, by Volume, Thousand Units, 2020-2031
Figure 25: Number of Tests Processed by Natera, Inc., 2018-2020
Figure 26: NGS-Based Screening Technologies by Major Companies
Figure 27: Reimbursement Policies Covering Prenatal Testing in the Europe Market
Figure 28: Births with Down’s Syndrome per 100,000 Live Births in Europe Region (2011-2018)
Figure 29: Examples of Investment and Funding by Key Companies
Figure 30: Classification of Tests in CLIA Program
Figure 31: Cost Range of NIPT in Major Countries
Figure 32: Reimbursement Scenario in Major Countries of the Global NIPT Market
Figure 33: Supply Chain of Global NIPT Market
Figure 34: Pre-COVID and Post-COVID Growth Trend of the Global NIPT Market, 2020-2025
Figure 35: Competitive Landscape (January 2017-October 2021)
Figure 36: Share of Key Developments and Strategies, January 2017-October 2021
Figure 37: New Offerings (by Company), January 2017-October 2021
Figure 38: Partnerships and Alliances (by Company), January 2017-October 2021
Figure 39: Product Approvals (by Company), January 2017-October 2021
Figure 40: Business Expansions (by Company), January 2017-October 2021
Figure 41: Merger and Acquisition Activities (by Company), January 2017-October 2021
Figure 42: Market Share Analysis of Global NIPT Market, 2020
Figure 43: Growth Share Matrix for NIPT Market (by Platform), 2019-2020
Figure 44: Global NIPT Segmentation (by Test)
Figure 45: Global NIPT Market (by Test), by Revenue, $Million, 2020-2031
Figure 46: Global NIPT Market for Panorama and Vistara (by Revenue), $Million, 2020-2031
Figure 47: Global NIPT Market for MaterniT GENOME, MaterniT 21 PLUS, and informaSeq, (by Revenue), $Million, 2020-2031
Figure 48: Global NIPT Market for Verifi and Verifi Plus Prenatal Tests (by Revenue), $Million, 2020-2031
Figure 49: Global NIPT Market for Harmony Test (by Revenue), $Million, 2020-2031
Figure 50: Global NIPT Market for NIFTY Test and NIFTY Test Pro (by Revenue), $Million, 2020-2031
Figure 51: Global NIPT Market for QNatal Advanced (by Revenue), $Million, 2020-2031
Figure 52: Global NIPT Market for PrenaTest, GeneSafe, and PrenatalSAFE (by Revenue), $Million, 2020-2031
Figure 53: Global NIPT Market for Bambni Test (by Revenue), $Million, 2020-2031
Figure 54: Global NIPT Market for IONA and Sage (by Revenue), $Million, 2020-2031
Figure 55: Global NIPT Market for Other Tests (by Revenue), $Million, 2020-2031
Figure 56: Global NIPT Segmentation (by Method)
Figure 57: Global NIPT Market (by Method), by Revenue, $Million, 2020-2031
Figure 58: Global NIPT Market (by Method), by Volume, Thousand Units, 2020-2031
Figure 59: Global NIPT Market for cfDNA (by Revenue), $Million, 2020-2031
Figure 60: Global NIPT Market for cfDNA (by Volume), Thousand Units, 2020-2031
Figure 61: Global NIPT Market for FCMB (by Revenue), $Million, 2020-2031
Figure 62: Global NIPT Market for FCMB (by Volume), Thousand Units, 2020-2031
Figure 63: Global NIPT Segmentation (by Platform)
Figure 64: Global NIPT Market (by Platform), by Revenue, $Million, 2020-2031
Figure 65: Global NIPT Market (by Platform), by Volume, Thousand Units, 2020-2031
Figure 66: Global NIPT Market for NGS (by Revenue), $Million, 2020-2031
Figure 67: Global NIPT Market for NGS (by Volume), Thousand Units, 2020-2031
Figure 68: Global NIPT Market for PCR (by Revenue), $Million, 2020-2031
Figure 69: Global NIPT Market for PCR (by Volume), Thousand Units, 2020-2031
Figure 70: Global NIPT Market for Other Platforms (by Revenue), $Million, 2020-2031
Figure 71: Global NIPT Market for Other Platforms (by Volume), Thousand Units, 2020-2031
Figure 72: Global NIPT Segmentation (by Application)
Figure 73: Global NIPT Market (by Application), by Revenue, $Million, 2020-2031
Figure 74: Global NIPT Market (by Application), by Volume, Thousand Units, 2020-2031
Figure 75: Global NIPT Market for Trisomy Detection (by Revenue), $Million, 2020-2031
Figure 76: Global NIPT Market for Trisomy Detection (by Volume), Thousand Units, 2020-2031
Figure 77: Global NIPT Market for Microdeletion Detection (by Revenue), $Million, 2020-2031
Figure 78: Global NIPT Market for Microdeletion Detection (by Volume), Thousand Units, 2020-2031
Figure 79: Global NIPT Market for Sex Chromosome Aneuploidy Detection (by Revenue), $Million, 2020-2031
Figure 80: Global NIPT Market for Sex Chromosome Aneuploidy Detection (by Volume), Thousand Units, 2020-2031
Figure 81: Global NIPT Market for Others (by Revenue), $Million, 2020-2031
Figure 82: Global NIPT Market for Others (by Volume), Thousand Units, 2020-2031
Figure 83: Global NIPT Segmentation (by End User)
Figure 84: Global NIPT Market (by End User), by Revenue, $Million, 2020 and 2031
Figure 85: Global NIPT Market (by End User), by Volume, Thousand Units, 2020 and 2031
Figure 86: Global NIPT Market for Hospital (by Revenue), $Million, 2020 and 2031
Figure 87: Global NIPT Market for Hospital (by Volume), Thousand Units, 2020 and 2031
Figure 88: Global NIPT Market for Clinics (by Revenue), $Million, 2020 and 2031
Figure 89: Global NIPT Market for Clinics (by Volume), Thousand Units, 2020 and 2031
Figure 90: Global NIPT Market for Diagnostic Labs (by Revenue), $Million, 2020 and 2031
Figure 91: Global NIPT Market for Diagnostic Labs (by Volume), Thousand Units, 2020 and 2031
Figure 92: Global NIPT Market for Others (by Revenue), $Million, 2020 and 2031
Figure 93: Global NIPT Market for Others (by Volume), Thousand Units, 2020 and 2031
Figure 94: Global NIPT Market (by Region)
Figure 95: Global NIPT Market (by Region), by Revenue, $Million, 2020-2031
Figure 96: Global NIPT Market (by Region), $Million, 2020-2031
Figure 97: Global NIPT Market (by Region), by Volume, Thousand Units, 2020 and 2031
Figure 98: Global NIPT Market (by Region), Thousand Units, 2020-2031
Figure 99: North America: NIPT Market (by Revenue), $Million, 2020-2031
Figure 100: North America: NIPT Market (by Volume), Thousand Units, 2020-2031
Figure 101: North America: Market Dynamics
Figure 102: North America: NIPT Market Share (by Country), by Revenue, $Million, 2020 and 2031
Figure 103: North America: NIPT Market Share (by Country), by Volume, Thousand Units, 2020 and 2031
Figure 104: Pricing Analysis by Leading NIPT Test, 2020
Figure 105: U.S. NIPT Market (by Revenue), $Million, 2020-2031
Figure 106: U.S. NIPT Market (by Volume), Thousand Units, 2020-2031
Figure 107: Organizations Offering NIPT Test in United States
Figure 108: Market Share Analysis of U.S. NIPT Market, $Million, 2020
Figure 109: Pricing Analysis by Leading NIPT Test in U.S., 2020
Figure 110: Canada NIPT Market (by Revenue), $Million, 2020-2031
Figure 111: Canada NIPT Market (by Volume), Thousand Units, 2020-2031
Figure 112: Organizations Offering NIPT Test in Canada
Figure 113: Market Share Analysis of Canada NIPT Market, $Million, 2020
Figure 114: Pricing Analysis by Leading NIPT Test in Canada, 2020
Figure 115: Europe: NIPT Market (by Revenue), $Million, 2020-2031
Figure 116: Europe NIPT Market (by Volume), Thousand Units, 2020-2031
Figure 117: Europe Market Dynamics
Figure 118: Europe: NIPT Market Share (by Country), by Revenue, $Million 2020 and 2031
Figure 119: Europe: NIPT Market Share (by Country), by Volume, Thousand Units 2020 and 2031
Figure 120: Pricing Analysis by Leading NIPT Test in EU-5, 2020
Figure 121: Germany NIPT Market (by Revenue), $Million, 2020-2031
Figure 122: Germany NIPT Market (by Volume), Thousand Units, 2020-2031
Figure 123: Organizations Offering NIPT Test in Germany
Figure 124: Market Share Analysis of Germany NIPT Market, $Million, 2019-2020
Figure 125: France NIPT Market (by Revenue), $Million, 2020-2031
Figure 126: France NIPT Market (by Volume), Thousand Units, 2020-2031
Figure 127: Organizations Offering NIPT Test in France
Figure 128: Market Share Analysis of France NIPT Market, $Million, 2019-2020
Figure 129: Italy NIPT Market (by Revenue), $Million, 2020-2031
Figure 130: Italy NIPT Market (by Volume), Thousand Units, 2020-2031
Figure 131: Organizations Offering NIPT Test in Italy
Figure 132: Market Share Analysis of Italy NIPT Market, $Million, 2019-2020
Figure 133: U.K. NIPT Market (by Revenue), $Million, 2020-2031
Figure 134: U.K. NIPT Market (by Volume), Thousand Units, 2020-2031
Figure 135: Organizations Offering NIPT Test in the U.K.
Figure 136: Market Share Analysis of U.K. NIPT Market, $Million, 2019-2020
Figure 137: Spain NIPT Market (by Revenue), $Million, 2020-2031
Figure 138: Spain NIPT Market (by Volume), Thousand Units, 2020-2031
Figure 139: Organizations Offering NIPT Test in the Spain
Figure 140: Market Share Analysis of Spain NIPT Market, $Million, 2019-2020
Figure 141: Russia NIPT Market (by Revenue), $Million, 2020-2031
Figure 142: Russia NIPT Market (by Volume), Thousand Units, 2020-2031
Figure 143: Organizations Offering NIPT Test in the Russia
Figure 144: Market Share Analysis of Russia NIPT Market, $Million, 2019-2020
Figure 145: Poland NIPT Market (by Revenue), $Million, 2020-2031
Figure 146: Poland NIPT Market (by Volume), Thousand Units, 2020-2031
Figure 147: Organizations Offering NIPT Test in Poland
Figure 148: Market Share Analysis of Poland NIPT Market, $Million, 2019-2020
Figure 149: Netherlands NIPT Market (by Revenue), $Million, 2020-2031
Figure 150: Netherlands NIPT Market (by Volume), Thousand Units, 2020-2031
Figure 151: Organizations Offering NIPT Test in Netherlands
Figure 152: Market Share Analysis of Netherlands NIPT Market, $Million, 2019-2020
Figure 153: Belgium NIPT Market (by Revenue), $Million, 2020-2031
Figure 154: Belgium NIPT Market (by Volume), Thousand Units, 2020-2031
Figure 155: Organizations Offering NIPT Test in Belgium
Figure 156: Market Share Analysis of Belgium NIPT Market, $Million, 2019-2020
Figure 157: Switzerland NIPT Market (by Revenue), $Million, 2020-2031
Figure 158: Switzerland NIPT Market (by Volume), Thousand Units, 2020-2031
Figure 159: Organizations Offering NIPT Test in Switzerland
Figure 160: Market Share Analysis of Switzerland NIPT Market, $Million, 2019-2020
Figure 161: Denmark NIPT Market (by Revenue), $Million, 2020-2031
Figure 162: Denmark NIPT Market (by Volume), Thousand Units, 2020-2031
Figure 163: Organizations Offering NIPT Test in Denmark
Figure 164: Market Share Analysis of Denmark NIPT Market, $Million, 2019-2020
Figure 165: Sweden NIPT Market (by Revenue), $Million, 2020-2031
Figure 166: Sweden NIPT Market (by Volume), Thousand Units, 2020-2031
Figure 167: Organizations Offering NIPT Test in Sweden
Figure 168: Market Share Analysis of Sweden NIPT Market, $Million, 2019-2020
Figure 169: Rest-of-Europe NIPT Market (by Revenue), $Million, 2020-2031
Figure 170: Rest-of-Europe NIPT Market (by Volume), Thousand Units, 2020-2031
Figure 171: APAC NIPT Market (by Revenue), $Million, 2020-2031
Figure 172: APAC: NIPT Market (by Volume), Thousand Units, 2020-2031
Figure 173: APAC Market Dynamics
Figure 174: APAC NIPT Market Share (by Country), by Revenue, 2020 and 2031
Figure 175: APAC NIPT Market Share (by Country), by Volume, 2020 and 2031
Figure 176: China NIPT Market (by Revenue), $Million, 2020-2031
Figure 177: China NIPT Market (by Volume), Thousand Units, 2020-2031
Figure 178: Japan NIPT Market (by Revenue), $Million, 2020-2031
Figure 179: Japan NIPT Market (by Volume), Thousand Units, 2020-2031
Figure 180: India NIPT Market (by Revenue), $Million, 2020-2031
Figure 181: India NIPT Market (by Volume), Thousand Units, 2020-2031
Figure 182: Australia NIPT Market (by Revenue), $Million, 2020-2031
Figure 183: Australia NIPT Market (by Volume), Thousand Units, 2020-2031
Figure 184: South Korea NIPT Market (by Revenue), $Million, 2020-2031
Figure 185: South Korea NIPT Market (by Volume), Thousand Units, 2020-2031
Figure 186: Hong Kong NIPT Market (by Revenue), $Million, 2020-2031
Figure 187: Hong Kong NIPT Market (by Volume), Thousand Units, 2020-2031
Figure 188: Malaysia NIPT Market (by Revenue), $Million, 2020-2031
Figure 189: Malaysia NIPT Market (by Volume), Thousand Units, 2020-2031
Figure 190: Indonesia NIPT Market (by Revenue), $Million, 2020-2031
Figure 191: Indonesia NIPT Market (by Volume), Thousand Units, 2020-2031
Figure 192: Vietnam NIPT Market (by Revenue), $Million, 2020-2031
Figure 193: Vietnam NIPT Market (by Volume), Thousand Units, 2020-2031
Figure 194: Thailand NIPT Market (by Revenue), $Million, 2020-2031
Figure 195: Thailand NIPT Market (by Volume), Thousand Units, 2020-2031
Figure 196: Philippines NIPT Market (by Revenue), $Million, 2020-2031
Figure 197: Philippines NIPT Market (by Volume), Thousand Units, 2020-2031
Figure 198: Rest-of-APAC NIPT Market (by Revenue), $Million, 2020-2031
Figure 199: Rest-of-APAC NIPT Market (by Volume), Thousand Units, 2020-2031
Figure 200: LATAM NIPT Market (by Revenue), $Million, 2020-2031
Figure 201: LATAM NIPT Market (by Volume), Thousand Units, 2020-2031
Figure 202: RoW NIPT Market (by Revenue), $Million, 2020-2031
Figure 203: RoW NIPT Market (by Volume), Thousand Units, 2020-2031
Figure 204: Shares of Key Company Profiles
Figure 205: Agilent Technologies, Inc.: Product Portfolio for Global NIPT Market
Figure 206: Agilent Technologies, Inc.: Overall Financials/Revenue, $Million, 2018-2020
Figure 207: Agilent Technologies, Inc.: Revenue (by Segment), $Million, 2018-2020
Figure 208: Agilent Technologies, Inc.: Revenue (By Region), $Millions, 2018-2020
Figure 209: Agilent Technologies, Inc.: R&D Expenditure, $Millions, 2018-2019
Figure 210: Agilent Technologies, Inc.: SWOT Analysis
Figure 211: Hoffmann-La Roche Ltd: Product Portfolio for Global NIPT Market
Figure 212: F. Hoffmann-La Roche Ltd: Overall Financials/Revenue, $Billion, 2018-2020
Figure 213: F. Hoffmann-La Roche Ltd: Revenue (by Segment), Billions, 2018-2020
Figure 214: F. Hoffmann-La Roche Ltd: Revenue (by Region), Billions, 2018-2020
Figure 215: F. Hoffmann-La Roche Ltd: R&D Expenditure, Billions, 2018-2020
Figure 216: F. Hoffmann-La Roche Ltd: SWOT Analysis
Figure 217: PerkinElmer, Inc.: Product Portfolio for Global NIPT Market
Figure 218: PerkinElmer, Inc.: Overall Financials/Revenue, $Million, 2018-2020
Figure 219: PerkinElmer, Inc.: Revenue (by Segment), Millions, 2018-2020
Figure 220: PerkinElmer, Inc.: Revenue (by Region), Millions, 2018-2020
Figure 221: PerkinElmer, Inc.: R&D Expenditure, Millions, 2018-2020
Figure 222: PerkinElmer, Inc.: SWOT Analysis
Figure 223: Quest Diagnostics Incorporated’s Product Portfolio for Global NIPT Market
Figure 224: Quest Diagnostics Incorporated.: Overall Financials/Revenue, $Million, 2018-2020
Figure 225: Quest Diagnostics Incorporated, Revenue (by Segment), Millions, 2018-2020
Figure 226: Quest Diagnostics Incorporated, SWOT Analysis
Figure 227: Illumina, Inc.: Product Portfolio for Global NIPT Market
Figure 228: Illumina, Inc.: Overall Financials/Revenue, $Million, 2018-2020
Figure 229: Illumina, Inc.: Revenue (by Segment), Millions, 2018-2020
Figure 230: Illumina, Inc.: Revenue (by Region), Millions, 2018-2020
Figure 231: Illumina, Inc.: R&D Expenditure, Millions, 2018-2020
Figure 232: Illumina, Inc.: SWOT Analysis
Figure 233: Myriad Genetics, Inc.: Product Portfolio for Global NIPT Market
Figure 234: Myriad Genetics, Inc.: Overall Financials/Revenue, $Million, 2018-2020
Figure 235: Myriad Genetics, Inc.: Revenue (by Product/Service), Millions, 2018-2020
Figure 236: Myriad Genetics, Inc.: R&D Expenditure, Millions, 2018-2020
Figure 237: Myriad Genetics, Inc.: SWOT Analysis
Figure 238: BGI: Product Portfolio for Global NIPT Market
Figure 239: BGI: SWOT Analysis
Figure 240: CENTOGENE N.V.: Product Portfolio for Global NIPT Market
Figure 241: CENTOGENE N.V.: Overall Financials/Revenue, $Million, 2018-2020
Figure 242: CENTOGENE N.V.: Revenue (by Segment), Millions, 2018-2020
Figure 243: CENTOGENE N.V.: Revenue (by Region), Millions, 2018-2020
Figure 244: CENTOGENE N.V.: R&D Expenditure, Millions, 2018-2020
Figure 245: CENTOGENE N.V.: SWOT Analysis
Figure 246: Laboratory Corporation of America Holdings: Product Portfolio for Global NIPT Market
Figure 247: Laboratory Corporation of America Holdings: Overall Financials/Revenue, $Million, 2018-2020
Figure 248: Laboratory Corporation of America Holdings: Revenue (by Segment), Millions, 2018-2020
Figure 249: Laboratory Corporation of America Holdings: Revenue (By Region), Millions, 2018-2020
Figure 250: Laboratory Corporation of America Holdings: SWOT Analysis
Figure 251: MedGenome Inc.: Product Portfolio for Global NIPT Market
Figure 252: MedGenome Inc.: SWOT Analysis
Figure 253: Annoroad Gene Technology: Product Portfolio for Global NIPT Market
Figure 254: Annoroad Gene Technology: SWOT Analysis
Figure 255: Natera, Inc.: Product Portfolio for Global NIPT Market
Figure 256: Natera, Inc.: Overall Financials/Revenue, $Million, 2018-2020
Figure 257: Natera, Inc.: Revenue (by Region), Millions, 2018-2020
Figure 258: Natera, Inc.: R&D Expenditure, Millions, 2018-2020
Figure 259: Natera, Inc.: SWOT Analysis
Figure 260: Yourgene Health PLC: Product Portfolio for Global NIPT Market
Figure 261: Yourgene Health PLC: Overall Financials/Revenue, $Million, 2018-2020
Figure 262: Yourgene Health PLC: Revenue (by Region), Millions, 2018-2020
Figure 263: Yourgene Health PLC: SWOT Analysis
Figure 264: Next Biosciences: Product Portfolio for Global NIPT Market
Figure 265: Next Biosciences SWOT Analysis
Figure 266: Eurofins Scientific: Product Portfolio for Global NIPT Market
Figure 267: Eurofins Scientific Overall Financials/Revenue, $Million, 2018-2020
Figure 268: Eurofins Scientific Revenue (by Region), Millions, 2018-2020
Figure 269: Eurofins Scientific: SWOT Analysis
Market Report Coverage
|
Non-Invasive Prenatal Testing (NIPT) Market |
|||
|
Base Year |
2020 |
Market Size in 2020 |
$2.52 Billion |
|
CAGR During Forecast Period (by Revenue) |
15.79% |
Value Projection and Estimation by 2031 |
$12.61 Billion |
|
CAGR During Forecast Period (by Volume) |
21.35% |
Market Volume in 2020 |
3,677 Thousand Units |
|
Forecast Period |
2021-2031 |
Volume Projection and Estimation by 2031 |
29,937 Thousand Units |
|
Research Hours |
|
Number of Tables |
16 |
|
Number of Pages |
301 |
Number of Figures |
269 |
|
Market Segmentation |
• By Test - Panorama and Vistara; MaterniT GENOME, MaterniT 21 PLUS, informaSeq, Verifi and Verifi Plus Prenatal Tests; Harmony Test; NIFTY Test and NIFTY Test Pro; QNatal Advanced; PrenaTest, GeneSafe, and PrenatalSAFE; Bambni Test; IONA and Sage; and Others • By Platform - PCR, Next-Generation Sequencing, and Others • By Method - cfDNA and FCMB • By End User - Hospitals, Clinics, Diagnostic Labs, and Others • By Application - Trisomy Detection, Microdeletion Detection, Sex Chromosome Aneuploidy Detection, Others |
||
|
Regional Segmentation |
• North America - U.S., Canada • Europe - Germany, U.K., France, Italy, Switzerland, Spain, Netherlands, Belgium, Russia, Poland, Denmark, Sweden, and Rest-of-Europe • Asia-Pacific - China, Australia, Japan, India, South Korea, Hong Kong, Malaysia, Indonesia, Vietnam, Thailand, Philippines, and Rest-of-Asia-Pacific • Latin America • Rest-of-the-World |
||
|
Growth Drivers |
• Increased Emphasis on Early Detection and Prevention • Availability of Advanced Screening Technologies • Increasing Consumer Demand • Shifting of Reimbursement Policies Toward More Genetics Coverage • High Incidence Rate of Down’s Syndrome • Rising Average Maternal Age • Increasing Prevalence of Genetic and Congenital Disorders |
||
|
Market Challenges |
• Stringent Regulatory Guidelines and Ethical Hurdles • Limitations of NIPT • Lack of Awareness Among Consumers • Alternative Screening and Testing Methods |
||
|
Market Opportunities |
• Capitalizing on the Potential Presented by the Emerging Markets in Asia • Availability of Direct-to-Consumer Tests • Focus on Pre-Implantation Genetic Diagnosis |
||
|
Key Companies Profiled |
Agilent Technologies, Inc., F. Hoffmann-La Roche Ltd, PerkinElmer, Inc., Quest Diagnostics Incorporated, Illumina, Inc., Myriad Genetics, Inc., BGI, CENTOGENE N.V., Laboratory Corporation of America Holdings, MedGenome Inc., Annoroad Gene Technology, Natera, Inc., Yourgene Health PLC, Next Biosciences, Eurofins Scientific |
||
Key Questions Answered in this Report:
• What is the importance of NIPT, and what are the different NIPT products/services available in the market? What are the different methods of NIPT, and what are the benefits and risks associated with it?
• What are the major technological advancements witnessed by the global NIPT market in the past four years, and what is the future scope of the market? What are the key trends of the global NIPT market as per the year 2020, and how is the market evolving currently?
• What was the market size of the global NIPT market in 2020, and what is the market size anticipated to be in 2031? What is the expected growth rate of the global NIPT market during the period 2021-2031?
• What is the market scenario and growth potential of different regions of the world, including North America, Europe, Asia-Pacific, and Rest-of-the-World?
• What are the major drivers, challenges, and opportunities of the global NIPT market?
• Who are the major key players of the global NIPT market? How much market share does each of these players occupy in the market in 2019? Which companies are anticipated to be highly disruptive in the future, and why?
• What is the regulatory scenario of the global NIPT market? What are the initiatives implemented by different governmental bodies and guidelines put forward to regulate the commercialization of NIPT products?
• What is the average NIPT cost in different countries? What is the reimbursement scenario of the global NIPT market, and what is the reimbursement rate in different countries of the world, including countries of North America, Latin America, Asia-Pacific, Europe, and the Middle East and Africa?
• What is the funding scenario of the market with respect to institutional and academic funding? What is the patent landscape of the market, and which companies stand out for registering the greatest number of patents?
• What are the key developmental strategies implemented by the key players of the global NIPT market to sustain the competition of the market? What is the percentage share of each of the key players in different key developmental strategies?
• What are the different NIPT tests available in the market, and which test type dominates the market in 2020 and 2031 in terms of value and volume?
• What is the global market size (by value and volume) of different types of products of the global NIPT market in 2020? What are the key trends of the market with respect to different kits, assays, and which product is expected to dominate the market in 2031?
• What are the different platforms supported by NIPT products? Which technology type dominated the market in 2020 and is expected to dominate in 2031 (by value and volume)?
• What are the different applications associated with NIPT? What was the contribution of each of the application areas in the global NIPT market for the period between 2021 and 2031 (by value and volume)?
• What is the global NIPT market size (by value and volume) based on different methods? Which method is currently leading the market and why? Which method is expected to lead the market during the forecast period?
• Who are the different end users of the global NIPT market (by value and volume)? Which end-user type is the major contributor of revenue in the market?
• Which region is expected to contribute the highest sales in the global NIPT market during 2020 and 2030? What are the leading countries of different regions that contribute significantly toward the growth of the NIPT market?
Report Summary
Market Overview
Non-invasive prenatal testing (NIPT) is a sophisticated method used for the screening of chromosomal abnormalities developing in the fetus. Currently, NIPT is considered a valuable test for the pregnant women to provide cost-effective and highly efficient early diagnosis of genetic disorders. The growth in the market is attributed to the increasing reimbursement policies and insurance coverage across the globe. Further, the continued significant investments for genome sequencing by healthcare companies to meet the industry demand and the growing incidence of genetic disorders are the prominent factors propelling the growth of the global NIPT market.
Advancements in genome sequencing technologies reduce turnaround time and the complexity of diagnosis with next generation sequencing (NGS). The NGS technology provides several opportunities to develop the non-invasive diagnostic procedures for an early and accurate detection of various genetic disorders. The life science industry is witnessing significant growth of NIPT tests developed using the NGS technology. Several biotechnology companies are now indulging in the research and development of such NGS-based NIPT products. Furthermore, the advent of genome sequencing technologies in the life science industry has enabled the companies to detect the genetic diseases at an early stage and provide accurate results to remain competitive in the market.
Our healthcare experts have found global NIPT market as one of the most rapidly evolving markets amongst the other prenatal testing industries. The purpose of this study is to gain a holistic view of the NIPT market in terms of various influencing factors, such as recent trends, regulatory requirements, and technological advancements of the market. The scope of this report constitutes a detailed study of the tests associated with the global NIPT market across different regions. The report presents the reader with an opportunity to unlock comprehensive insights with respect to the market and helps in forming well-informed strategic decisions. The research uncovers some of the substantial parameters that must be taken into consideration before entering the market.
The report includes an in-depth examination of the key players and recent developments taking place in this market. Moreover, the report includes chapters on market dynamics (market drivers, opportunities, and challenges) and industry analysis as well. Also, aims at answering various aspects of the global NIPT market with the help of the key factors driving the market, restraints, and challenges that can inhibit the overall market growth and the current growth opportunities that are going to shape the future trajectory of the market expansion
Within the research report, the market has been segmented into ‘platforms,’ ‘tests,’ ‘methods,’ ‘applications,’ ‘end-user’, and ‘regions.’. Each of these segments covers the inclination of the market revenue, underlying patterns, snapshot of the market over the projected years, and trends by using analytics on the primary and secondary data obtained.
Competitive Landscape
The NIPT market is currently at a blooming phase, with the presence of various juggernauts such as Laboratory Corporation of America Holdings, F. Hoffmann-La Roche Ltd, Illumina, Inc., Agilent Technologies, Inc., BGI, and PerkinElmer Inc., as well as other medium and small-medium enterprises, that are offering wide range of NIPT products and services in the market. Several companies are attempting to enter the market and sustain themselves in the competition by adopting different strategies varying from partnerships and collaborations to business expansions and product launches.
Global Non-Invasive Prenatal Testing (NIPT) Market
Focus on Method, Test, Platform, End User, Application and Country Analysis - Analysis and Forecast, 2020-2031
Some Faq's
Frequently Asked Questions
The global non-invasive prenatal market was valued at $2.52 billion in 2020 and is expected to reach $12.61 billion by 2031.
The top market players are Agilent Technologies, Inc., F. Hoffmann-La Roche Ltd, PerkinElmer, Inc., Quest Diagnostics Incorporated, Illumina, Inc., Myriad Genetics, Inc., BGI, CENTOGENE N.V., Laboratory Corporation of America Holdings, MedGenome Inc., Annoroad Gene Technology, Natera, Inc., Yourgene Health PLC, Next Biosciences, Eurofins Scientific.
Factors driving the growth of the non-invasive prenatal testing market are increased emphasis on early detection and prevention, availability of advanced screening technologies, increasing consumer demand, shifting of reimbursement policies toward more genetics coverage, high incidence rate of down syndrome, rising average maternal age, and increasing prevalence of genetic and congenital disorders.
Some of the main challenges restricting the growth of the non-invasive prenatal testing market are stringent regulatory guidelines and ethical hurdles, limitations of NIPT, lack of awareness among consumers, and alternative screening and testing methods.
The potential opportunities that are likely to boost the growth of the non-invasive prenatal testing market are capitalizing on the potential presented by the emerging markets in Asia, and availability of direct-to-consumer tests, and focus on pre-implantation genetic diagnosis.
Similar Product
You may also like
Published Year: 2021
Global In-Vitro Fertilization Market: Focus on Products, Types, Procedures, and End Users, Country D
The global market for in-vitro fertilization is predicted to grow at a CAGR of 9.37% over the...
Published Year: 2019
Asia-Pacific In-Vitro Fertilization Market – Analysis and Forecast, 2019-2029: Focus on Device Typ
The Asia-Pacific IVF market is valued at $6.99 billion in 2018, and is expected to witness a...